Reata Pharmaceuticals, Inc.
1950 Stemmons Freeway, Suite 5001
Dallas
Texas
75207
United States
Tel: 214-800-8700
Fax: 214-722-0867
Website: http://www.reatapharma.com/
Email: info@reatapharma.com
148 articles with Reata Pharmaceuticals, Inc.
-
Reata Pharmaceuticals Announces Participation in the Citi 17th Annual BioPharma Conference
9/6/2022
Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that management will participate in investor meetings at the Citi 17th Annual BioPharma Conference on September 7 – 8, 2022 in Boston, Massachusetts.
-
Reata Pharmaceuticals Announces Three Month Extension of the Review Period for New Drug Application for Omaveloxolone for the Treatment of Friedreich’s Ataxia
8/9/2022
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced that on August 8, 2022, after the U.S. financial markets closed, we received a communication from the U.S. Food and Drug Administration informing us that they have extended the review timeline for the New Drug Application for omaveloxolone for the treatment of Friedreich’s ataxia by three months.
-
Reata Pharmaceuticals, Inc. Announces Second Quarter 2022 Financial Results and Provides an Update on Clinical Development Programs
8/8/2022
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced financial results for the second quarter of 2022 and provided an update on the Company’s business operations and clinical development programs.
-
Reata Pharmaceuticals, Inc. to Report Second Quarter 2022 Financial Results and to Provide an Update on Clinical Development Programs on August 8, 2022
8/1/2022
Reata Pharmaceuticals, Inc. announced that it will report financial results for the second quarter ended June 30, 2022, and provide an update on the Company’s business operations and clinical development programs on August 8, 2022, before the U.S. financial markets open.
-
Reata Announces the Appointment of Steven W. Ryder, M.D. to its Board of Directors
7/11/2022
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced the appointment of Steven W. Ryder, M.D. to its Board of Directors, effective July 11, 2022.
-
Reata Pharmaceuticals Announces FDA Filing Acceptance and Priority Review Designation for the NDA for Omaveloxolone for the Treatment of Patients with Friedreich’s Ataxia
5/26/2022
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced that the U.S. Food and Drug Administration has accepted for filing and granted Priority Review of its New Drug Application for omaveloxolone for the treatment of patients with Friedreich’s ataxia.
-
Reata Pharmaceuticals, Inc. Announces First Quarter 2022 Financial Results and Provides an Update on Clinical Development Programs
5/10/2022
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced financial results for the first quarter of 2022 and provided an update on the Company’s business operations and clinical development programs.
-
Reata Pharmaceuticals, Inc. to Report First Quarter 2022 Financial Results and to Provide an Update on Clinical Development Programs on May 10, 2022
5/2/2022
Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” “our,” “us,” or “we”), a clinical-stage biopharmaceutical company, today announced that it will report financial results for the first quarter ended March 31, 2022, and provide an update on the Company’s business operations and clinical development programs on May 10, 2022, before the U.S. financial markets open.
-
Reata Pharmaceuticals Completes Rolling Submission of New Drug Application for Omaveloxolone for the Treatment of Patients with Friedreich’s Ataxia
3/31/2022
Reata Pharmaceuticals, Inc. today announced the completion of the rolling submission of a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for omaveloxolone for the treatment of patients with Friedreich’s ataxia.
-
Lately, there has been heightened attention to briefing documents in the CNS space, a notoriously tricky area to get drugs approved, which can affect company stock prices.
-
Reata Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2021 Financial Results and Provides an Update on Clinical Development Programs
2/28/2022
Reata Pharmaceuticals, Inc. today announced financial results for the quarter and full year ended on December 31, 2021 and provided an update on the Company’s business operations and clinical development programs.
-
The FDA said that the shared NDA documents did not show ample proof that bardoxolone methyl effectively slows down kidney function loss in patients with Alport syndrome.
-
Reata Pharmaceuticals Receives Complete Response Letter From The FDA for Bardoxolone for the Treatment of Patients with Chronic Kidney Disease Caused by Alport Syndrome
2/25/2022
Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), today announced that the U.S. Food and Drug Administration (“FDA”) has issued a Complete Response Letter (“CRL”) regarding the New Drug Application (“NDA”) for bardoxolone methyl (“bardoxolone”) for the treatment of patients with chronic kidney disease (“CKD”) caused by Alport syndrome.
-
The end of February picks up significantly from early this year for the U.S. Food and Drug Administration and its PDUFA dates.
-
Reata Pharmaceuticals, Inc. To Report Fourth Quarter and Full Year 2021 Financial Results and To Provide an Update on Development Programs on February 28, 2022
2/18/2022
Reata Pharmaceuticals, Inc. today announced that it will report financial results and provide an update on the Company’s business operations and clinical development programs pre-market on February 28, 2022.
-
Reata Pharmaceuticals Initiates Rolling Submission of New Drug Application with U.S. FDA for Omaveloxolone for the Treatment of Patients with Friedreich’s Ataxia
1/31/2022
Reata Pharmaceuticals, Inc. (Nasdaq: RETA), (“Reata,” the “Company,” “our,” “us,” or “we”), a clinical-stage biopharmaceutical company, today announced that the company has initiated a rolling submission of a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for omaveloxolone for the treatment of patients with Friedreich’s ataxia.
-
Shares of Reata Pharmaceuticals have plunged nearly 40% in premarket trading after an FDA advisory panel recommended against the approval of its Alport syndrome disease treatment, bardoxolone.
-
Reata Pharmaceuticals Announces Outcome of FDA Advisory Committee Meeting of Bardoxolone for the Treatment of Patients with Chronic Kidney Disease Caused by Alport Syndrome
12/8/2021
Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), today announced the outcome of the U.S. Food and Drug Administration (“FDA”) Cardiovascular and Renal Drugs Advisory Committee (“Committee”) meeting on bardoxolone methyl (“bardoxolone”) for the treatment of patients with chronic kidney disease (“CKD”) caused by Alport syndrome.
-
Reata Pharmaceuticals Stock Trading Halted Today; FDA Advisory Committee to Discuss Bardoxolone for the Treatment of Patients With Chronic Kidney Disease Caused by Alport Syndrome
12/8/2021
Reata Pharmaceuticals, Inc announced today that Nasdaq has halted trading of the Company’s common stock.
-
In the staff documents, the FDA scientists expressed concerns over the Reata clinical data that was submitted.